Replies to post #341400 on Elite Pharmaceuticals Inc (ELTP)

[IB_]

It looks to me as if ELTP management or their minions may be here trying to strongly influence shareholder opinion on how Nasrat is operating as CEO of OUR company while also owning his private Pharma company and do deals between the two..................................

I do NOT trust the CEO any longer, not even a little bit,

IB_

[DR Ryan]

And again, that is years ago. Let's focus on going forward. Crunching the numbers on dead drugs is pointless and goes nowhere.

[meshcan]

FACT CHECKING…Annual R&D expenses for Elite over time…
2020 = 5,532,462
2019 = 7,599,820
2018 = 9,621,365
2017 = 8,301,693
2016 = 2,903,178
2015 = 2,904,114
2014 = 2,105,725

2013 *

*Nasrat was named CEO August 2013, so his tenure actually began in Fiscal Year 2014. Thus, the FY 2013 R&D of $3,959,316 was NOT during his tenure as CEO.

By adding all the R&D expenses during Nasrat’s tenure as CEO, the totals are $38,968,357. That is 39% of the claimed $100M

As Bob Uecker would say - "Juuuuuust a little bit outside!"

Trying to keep it real.

[The ELTP King]

We STOLE $7.5 million from Epic though.

That's $30M just to get the CRL. How much was spent after the CRL? Costs included multiple reformulations and bioequivalence studies, including a pivotal BE study. $50M for SequestOx alone stands up.